[
    [
        {
            "time": "2020-08-18",
            "original_text": "Lilly's 2nd Potential Coronavirus Antibody Candidate in Phase I",
            "features": {
                "keywords": [
                    "Lilly",
                    "Coronavirus",
                    "Antibody",
                    "Phase I"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "Lilly's 2nd Potential Coronavirus Antibody Candidate in Phase I",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-09-15",
            "original_text": "EXPLAINER-What are antibody therapies and who is developing them for COVID-19?",
            "features": {
                "keywords": [
                    "antibody",
                    "therapies",
                    "COVID-19",
                    "developing"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "EXPLAINER-What are antibody therapies and who is developing them for COVID-19?",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-08-13",
            "original_text": "Hexo Corp. (HEXO) to Post Q3 Earnings: What's in the Offing?",
            "features": {
                "keywords": [
                    "Hexo",
                    "Corp.",
                    "Q3",
                    "Earnings"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "cannabis",
                    "consumer goods"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Hexo Corp. (HEXO) to Post Q3 Earnings: What's in the Offing?",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-08-25",
            "original_text": "First patient dose delivered for Lilly's tirzepatide cardiovascular outcomes trial",
            "features": {
                "keywords": [
                    "Lilly",
                    "tirzepatide",
                    "cardiovascular",
                    "outcomes",
                    "trial"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "First patient dose delivered for Lilly's tirzepatide cardiovascular outcomes trial",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]